Germ Cell Tumor Management in the Central Nervous System

Primary central nervous system germ cell tumours (CNS GCTs) are rare neoplasms that predominantly affect children and young adults, with a higher incidence in certain Asian populations. They are broadly divided into germinomas and non-germinomatous germ cell tumours (NGGCTs), each with distinct histopathology, molecular profiles and clinical behaviour. Diagnosis relies on a combination of neuroimaging, tumour markers in serum and cerebrospinal fluid, and sometimes surgical biopsy. Magnetic resonance imaging remains the cornerstone for localisation and surgical planning, while markers such as β-hCG and αFP aid subtype discrimination. Management strategies are tailored according to histology, tumour location, extent of spread and patient age. Germinomas typically exhibit excellent radiosensitivity and chemosensitivity, allowing combined protocols that reduce long-term neurotoxicity. NGGCTs demand more intensive multimodal approaches, incorporating platinum-based chemotherapy followed by craniospinal irradiation or whole-ventricular radiotherapy with boost fields. Surgical intervention is reserved for histological confirmation, relief of obstructive hydrocephalus or resection of residual disease. Advances in radiotherapy techniques, including proton beam therapy, aim to maintain high cure rates while mitigating late effects on growth, endocrine function and cognitive outcome. Emerging targeted agents directed at activated KIT, RAS/MAPK and PI3K/AKT/mTOR pathways, as well as immunotherapeutic strategies against immune checkpoints, promise to refine risk-adapted treatment and improve quality of life.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Germ Cell Tumor Management in the Central Nervous System publication trend

The graph below shows the total number of articles in germ cell tumor management in the central nervous system across all publications each year (not limited to Nature Index journals).

Technical terms

Germinoma: Highly radiosensitive central nervous system germ cell tumour subtype with excellent cure rates.

Non-germinomatous germ cell tumour (NGGCT): Aggressive CNS GCT category encompassing embryonal carcinoma, yolk sac tumour, choriocarcinoma and teratoma.

Craniospinal irradiation (CSI): Radiotherapy technique that delivers radiation to the entire neuroaxis to treat or prevent leptomeningeal spread.

Immune checkpoint: Regulatory proteins such as PD-1 and CTLA-4 on T cells that can be targeted to enhance antitumour immunity.

Proton beam therapy: Radiotherapy modality using charged particles to confine dose to the tumour and spare adjacent healthy tissue.

References

1. Advances in genetic abnormalities, epigenetic reprogramming, and immune landscape of intracranial germ cell tumors. Acta Neuropathologica Communications (2023).
2. The clinical significance of T cell infiltration and immune checkpoint expression in central nervous system germ cell tumors. Frontiers in Immunology (2025).
3. Intracranial Germinomas: Diagnosis, Pathogenesis, Clinical Presentation, and Management. Current Oncology Reports (2023).
4. An update on the clinical diagnostic value of β-hCG and αFP for intracranial germ cell tumors. European Journal of Medical Research (2016).
5. Differential dosimetric benefit of proton beam therapy over intensity modulated radiotherapy for a variety of targets in patients with intracranial germ cell tumors. Radiation Oncology (2015).